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Abstract
Background Microwave endometrial ablation is a new,
minimally invasive treatment option for menorrhagia. Its
popularity in many countries is increasing due to its safety
and simplicity.
Cases We treated menorrhagia due to submucosal myo-
mas in two patients with a modiWed microwave endometrial
ablation device. Surgery was contraindicated in the Wrst
patient secondary to medical co-morbidities and in the sec-
ond patient because of acute hemorrhagic shock. In both
cases, the operation was highly eVective and each patient
was satisWed with her treatment outcome.
Conclusion Given its safety, simplicity, and eVectiveness,
microwave endometrial ablation may be widely adopted for
the emergent control of uterine bleeding in patients with
poor surgical candidates.
Keywords MEA · Menorrhagia · Multiple systemic 
diseases · Acute hemorrhagic shock
Abbreviations
MEA Microwave endometrial ablation
Introduction
Endometrial ablation (EA) is a minimally invasive surgical
treatment for menorrhagia. Microwave endometrial abla-
tion (MEA) is a second-generation method of EA. It uti-
lizes microwaves at a Wxed frequency, delivered by
inserting a microwave probe into the uterine cavity. The
microwaves destroy the basal layer of the endometrium and
the glands by heating them to over 60°C. The remainder of
the uterus is spared. MEA was introduced in 1995 and was
found to be an eVective, less invasive alternative to hyster-
ectomy [1]. The procedure was subsequently modiWed to
make it safer and easier. MEA has several advantages over
other treatments of menorrhagia including hysterectomy
and uterine artery embolization. It is quick and easy to per-
form, requiring minimal operative skill, and has few com-
plications. Preoperative preparation is straightforward and
the procedure can be done at a day surgery center. Thus,
MEA is relatively cost eVective [2]. Recently, a number of
cases documenting successful treatment of menorrhagia
with MEA in patients with medical complications have
been reported [2,  3]. We report two additional cases of
heavy uterine bleeding caused by submucous myomas suc-
cessfully controlled by MEA. One of the patients had mul-
tiple systemic disorders rendering her a poor surgical
candidate. The other patient was treated with MEA emer-
gently in order to control uterine bleeding that was leading
to hemorrhagic shock. Neither patient had intra- or post-
operative complications. At follow-up, both patients expe-
rienced complete resolution of menorrhagia with a dramatic
reduction in uterine size.
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Materials and methods
SpeciWc case details are discussed subsequently. Both
patients were perimenopausal and had contraindications to
hysterectomy. We conWrmed the site, size, and vascularity of
submucosal myomas by magnetic resonance imaging (MRI)
and transvaginal ultrasound. Endometrial malignancy was
ruled out by diagnostic imaging (MRI and TVS) and cytolog-
ical examinations. Written informed consents were obtained
from both patients. Permission to perform the MEA was
obtained from the ethical committee of the Shimane Univer-
sity hospital. MEA was performed under spinal anesthesia
using a device manufactured by Alfresapharma (Osaka,
Japan). The device consists of a Sounding Applicator and a
microwave generator. The applicator is only 4 mm in diame-
ter and 20 cm in length, terminating at the tip with a curved
microwave applicator. The 2.45-GHz microwaves are sup-
plied by a Microtaze AZM-520 microwave generator. It is in
contrast to a previous microwave device which is 8.5 mm in
diameter and has a non-bending tip and can generate micro-
waves at 9.2 GHz [1]. This modiWed shape facilitates the eas-
ier and safer operation of this device, even in a large and
distorted uterine cavity [4]. For each irradiation site, micro-
waves were transmitted at 70 W for approximately 50 s. Nei-
ther patient had any intra- or post-operative complications.
Both the patients had post-operative visits at 1 week and at
1–3 months that included a careful interview regarding uter-
ine bleeding and clinical examination. MRI images after
MEA showed a gradual reduction in the size of the myomas
and uterus. Gadolinium (Gd) enhanced MRI demonstrated
the necrotic endometrium as an avascular area.
Case 1
The patient was a 40-year-old woman with history of
severe hypertension, cerebral stroke, and atrial Wbrillation
who presented with severe menorrhagia since several
months before operation. On examination, she was found to
be anemic. Abdominal examination revealed a markedly
enlarged uterus. Transvaginal ultrasonography demon-
strated a myoma measuring 5 cm £ 4c m£ 5 cm, located
on posterior wall. Although the patient was parous, she was
a poor candidate for hysterectomy under general anesthesia.
Thus, we opted for MEA under the guidance of transab-
dominal ultrasonography. The patient was not pretreated
with either gonadotropin-releasing hormone (Gn-RH) ana-
logues or danazol for endometrial preparation; MEA was
performed under spinal anesthesia. The total operating time
was 21 min and the estimated blood loss was of insuYcient
volume to record. There were no post-operative complica-
tions. An MRI was performed at 7 days, 1 month, and
3 months after MEA (Fig. 1). The MRI on the Wrst week
after MEA showed almost no change of myoma size, but
there was a small area of avascularity in the endometrium
on the posterior wall close the myoma. A Gd-enhnaced T1
MRI at 3 months after treatment shows that myoma size
was reduced remarkably and the uterine lining was partially
replaced by avascular area (Fig. 1). For case 1, a Gd-
enhanced T1-weighted image 3 months after the MEA
revealed that the intramural myoma on the posterior wall
had shrunk to 3 cm £ 2c m£ 3 cm. The patient resumed
her regular menstrual cycle the next month with under-
average Xow.
Case 2
The patient, a 51-year-old woman, presented to the emer-
gency department with heavy vaginal bleeding leading to
hemorrhagic shock. The transvaginal ultrasonography
showed a submucosal myoma measuring 2 cm £ 3c m£
2 cm. After initial resuscitation, we opted to ablate the
bleeding area using microwaves. Under spinal anesthesia,
Fig. 1 MRI images of case 1. a Axial and T1-weighted images before
MEA. The uterine cavity is enlarged and distorted by a submucous
myoma,  b and c Gd-enhanced T1-weighted images 7 days and
3 months after MEA showing a partially necrotic endometrium. The
myoma is smaller than before the MEAArch Gynecol Obstet (2009) 280:279–282 281
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MEA was performed. The total operative time was 30 min,
the estimated blood loss was 90 ml, and there were no
intra- or post-operative complications. MRI was performed
at 5 days, and 3 months post-operatively (Fig. 2). The 3-
months post-operative MRI revealed that the submucosal
myoma on the anterior wall had shrunk to the extent that it
became almost undetectable and the uterine lining was par-
tially replaced by an avascular area (Fig. 2). On follow-up,
the patient was satisWed with the treatment. She resumed
regular menstrual cycles with normal blood loss at 60 days
post-operative.
Discussion
Menorrhagia and metrorrhagia are two of the most fre-
quently reported gynecologic concerns. The search is ongo-
ing for new treatments for abnormal uterine bleeding. Many
of the current medical therapies have side eVects that limit
their duration of use. Although hysterectomy is curative for
menorrhagia, there is signiWcant morbidity and mortality
associated with the operation. In an attempt to reduce hys-
terectomy rates and the rates of its associated complica-
tions, minimally invasive procedures including uterine
artery embolization, hysteroscopic myomectomy, focused
ultrasound, and cryomyolysis have been developed. Unfor-
tunately, each of these alternatives has a risk of its own.
These procedures may result in any of the following com-
plications, such as: Xuid overload, uterine perforation,
infection, thermal injury, hemorrhage, deep venous throm-
bosis, etc. In addition, these procedures can be technically
diYcult for general practitioners to perform. Recently,
eVorts have been directed to develop new techniques for
destroying the endometrium that are safer and simpler to
perform. The new devices ablate the endometrium with
lasers, radiofrequency waves, electrocautery, microwaves,
heated saline, or a heated balloon. These procedures can be
performed with minimal surgical skill in patients who
would otherwise be poor surgical candidates. Blood loss is
minimal and complications are few. The short-term cura-
tive rate of MEA is similar to that of a total hysterectomy.
In terms of operative complications and post-operative
recovery, MEA is obviously superior to total hysterectomy.
It can also be used to treat larger or irregular cavities [4],
and has even been used successfully in a didelphic uterus
[5]. MEA is only contraindicated when the uterine bleeding
arises from a malignancy. There is, however, one case
report documenting successful MEA without recurrence for
endometrial hyperplasia with atypia. An increasing number
of reproductive-aged women are choosing endometrial
Fig. 2 MRI images of case 2, 
5d a y s  a n d  3m o n t h s  a f t e r  M E A .  
a, b T2-weighted images show 
gradual shrinkage of the myoma 
and c, d Gd-enhanced T1-
weighted images show the 
partially necrotic endometrium 
following MEA282 Arch Gynecol Obstet (2009) 280:279–282
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ablation as a way to manage erratic perimenopausal bleed-
ing. The fertility after endometrial destruction is low and is
reported to be 0.7%, although there is a report of pregnancy
after MEA [6]. Thus women considering this procedure
should be carefully counseled that though pregnancy fol-
lowing ablation is possible, desired fertility is a contraindi-
cation given that EA can signiWcantly increase the risk of
obstetric complications mainly due to the development of
uterine synechiae.
Microwave ablation therapy has been extensively uti-
lized in the liver and kidney. The use of microwaves at
9.2 GHz in gynecology was Wrst reported in the form of
MEA at the University of Bath [7]. This particular device,
however, was unsuitable for treating uterine cavities
remarkably distorted or enlarged by uterine myomas.
Recently, Kanaoka et al. [4] developed a special instrument
which delivers 2.45-GHz microwaves through a thin curved
microwave applicator that conforms to the curvature of the
uterine cavity. This applicator may be used in cavities up to
16 cm in length and can treat myomas bigger than 3 cm [4].
MEA has been evaluated extensively in randomized tri-
als against Wrst- and second-generation endometrial abla-
tive techniques and has been shown to have good outcomes
with a high level of patient satisfaction [1]. We used the
device modiWed by Kanaoka et al. [4]. In the case of our
Wrst patient, a poor surgical candidate, the size of her
myoma exceeded that which could be treated with a con-
ventional MEA device. In the case of the second patient,
MEA was useful emergently to control a life-threatening
hemorrhage. Neither of the patients experienced any
signiWcant intra- or post-operative complications related to
the procedure. Moreover, menorrhagia was successfully
controlled and subsequent cycles were normal. MEA there-
fore is a promising new method for controlling life-threat-
ening uterine bleeding in patients who are poor surgical
candidates.
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